An observational study in Organoid, Esophageal Cancer and Chemoradiation, sponsored by University Medical Center Groningen. Recruiting at 3 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-28.
Sponsored by University Medical Center Groningen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Esophageal Neoplasms by University Medical Center Groningen — 8 open to participants now, 8 under way, none of them phase 3. Esophageal Neoplasms · University Medical Center Groningen.
Among the 16 studies in Esophageal Neoplasms by University Medical Center Groningen, this one is one of 2 that started in 2017, is one of 7 observational ones, and was the 7th registered.
1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.
Browse Esophageal Neoplasms studies →8 of the 16 studies in Esophageal Neoplasms by University Medical Center Groningen are open now, in 3 countries. Recruiting first, the newest first:
University Medical Center Groningen · Sites in Netherlands
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18–100
University Medical Center Groningen · Sites in Netherlands
Ages 18+
University Medical Center Groningen · Sites in Belgium, Netherlands, United Kingdom
Ages 18+
By country, each count listing its studies:
Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 1
First in 2009; this study’s year is marked. 2 started in 2017.
This study's planned enrollment of 100 is below the median of 200 across 433 observational studies indexed under Esophageal Neoplasms.
Median enrollment 15 across the 9 interventional studies, 100 across the 7 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Medical Center Groningen is the lead sponsor of 627 studies on the registry; 175 are open to participants now.
2 of the studies in Esophageal Neoplasms by University Medical Center Groningen that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07108855University Medical Center GroningenDetection of Upper Gastrointestinal Tumour Depth and Demarcation Using Systemic Administration of Indocyanine Green During Endoscopic Submucosal Dissection | 2027-06-01 |
| NCT04986293University Medical Center GroningenCPAP or BiPAP for Motion Mitigation During Radiotherapy | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Esophageal Neoplasms by University Medical Center Groningen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Rationale: Current standard treatment of localized esophageal cancer (EC) with neoadjuvant chemoradiotherapy (nCRT) followed by esophagectomy with curative intent results in 30% complete, 40-60% partial and 20% no-response at pathologic examination. Clinical response of nCRT is usually evaluated with PET-CT. However, response measurements are currently still insufficient in optimizing EC treatment. Proper pre-surgical response prediction may allow individualized treatment with esophagus-preservation in complete responders or switching to an alternative treatment in non-responders. Interestingly, in many tumors, a subset of cells has been found to possess cancer stem cell (CSC) properties with associated signaling as drivers of tumor (re-)growth and therapy resistance. Response of CSC-derived tissue resembling in vitro cultured tumor organoids may reflect patient's tumors sensitivity to therapy.
Objective: To create a patient derived organoid model for EC patients to predict the pathologic tumor response to nCRT in clinical practice. This will allow a more personalized approach in future treatment of locally advanced EC.
Study design: Fresh esophageal tumor material will be collected during diagnostic endoscopic ultrasound (EUS) in participating patients. These biopsies will be used to select cancer stem cells, which will be cultured to derive organoids (esophageal cancer patient derived organoids; EC-PDO). When the EC-PDO contain sufficient cells, these cells will be treated with radiotherapy and/or chemotherapy in order to obtain dose-response curves. The response of these EC-PDOs will be compared to the actual tumor response to nCRT treatment in these EC patients, which will be assessed at the definitive pathologic examination of the resection specimen after esophagectomy with curative intent.
Study population: All patients with curatively treatable and resectable esophageal cancer (adenocarcinoma or squamous cell carcinoma) can be included in this trial.
Main study parameters/endpoints: The main endpoint is response prediction to chemoradiotherapy by EC-PDO; the steepness of the dose response survival curve in the organoids in relation to the pathologic response after resection in the clinical situation.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The patients will be asked to undergo 3 to 6 additional biopsies during endoscopic ultrasonography (EUS) for the TNM staging of the tumor. The risk of these additional biopsies is not greater than the biopsies for the diagnosis of EC. The patient will not benefit from participation in this trial.
For the future approach we can get more insight into the mechanism of (chemo)radiation response or resistance to nCRT, which might lead to a better patient selection and more individualized esophageal cancer treatment in the future. This improvement in selection and treatment can result in less over or under-treatment of these EC patients.
All patients with histologically proven adenocarcinoma or squamous cell carcinoma of the esophagus, who are candidates for nCRT followed by resection, can be included in this trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Response prediction by EC-PDO
The main endpoint is response prediction by EC-PDO; the steepness of the dose response survival curve in relation to the pathologic response after resection.
Time frame: january 2020
EC-PDO growth rate in-vivo
Time frame: December 2018- febr 2019
Stem cell characterization measured by the amount of CD24-/CD44+
Time frame: March 2018
Radio/Chemo-sensitivity/resistance; the effective dose 50% (ED50%) of CSCs enriched subpopulation will be compared with the ED50% esophageal cancer cell lines.
Time frame: december 2019/january 2020
Clinical response: based on PET-CT (standard): complete, partial or no response
Time frame: December 2019/January 2020
Disease free survival (DFS) in months in patients
Time frame: December 2020/January 2021
Overall survival (OS) in months
Time frame: December 2020/January 2021
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2017 (actual). Primary completion is estimated for Dec 2023, 72 months after the start.
Of 152 non-industry observational studies under Esophageal Neoplasms, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 252. This study's planned 72 months is below that.
Counting every sponsor, half of 174 studies reached it within 64 months; a quarter within 33 and three quarters within 252.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Medical Center Groningen →